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Abstract: Lipoproteins containing apolipoprotein B modify associations of elevated urinary albumin
excretion (UAE) with cardiovascular disease (CVD). Additionally, it is known that elevated UAE
alters high-density lipoprotein functionality. Accordingly, we examined whether HDL features
might also modify UAE-associated CVD. Multivariable Cox proportional-hazards modeling was
performed on participants of the PREVEND (Prevention of Renal and Vascular Endstage Disease)
study at the baseline screening with standard lipid/lipoprotein analyses and, three-to-four years later
(second screen), with nuclear magnetic resonance lipoprotein analyses focusing on HDL parameters
including HDL particle (HDL-P) and apolipoprotein A-I concentrations. These were used with UAE
and derived measures of HDL apoA-I content (apoA-I/HDL-C and apoA-I/HDL-P) in risk models
adjusted for gender, age, apoB, diabetes, past CVD history, CRP and GFR. Interaction analysis was
also performed. Baseline screening revealed significant associations inverse for HDL-C and apoA-I
and direct for apoA-I/HDL-C. The second screening demonstrated associations inverse for HDL-P,
large HDL-P, medium HDL-P, HDL size, and apoA-I/HDL-P. Significant interactions with UAE
included apoA-I/HDL-C at the baseline screening, and apoA-I/HDL-P and medium HDL-P but
not apoA-I/HDL-C at the second screening. We conclude that features of HDL particles including
apoA-I/HDL-P, indicative of HDL apoA-I content, and medium HDL-P modify associations of
elevated UAE with CVD risk.
Keywords: albuminuria; urinary albumin excretion; HDL; apolipoprotein A-I; HDL subfractions
1. Introduction
Elevated urinary albumin excretion (UAE) is well known to be associated with cardiovascular
disease (CVD) risk [1–8]. Furthermore, it is likely that coexisting atherogenic lipoprotein abnormalities
in individuals with elevated UAE modify CVD risk in this setting [9,10], a notion that is consistent with
reports of elevated levels of plasma atherogenic apolipoprotein B (apoB) particles in individuals with
proteinuria [11–15]. In this case, elevated UAE and atherogenic apoB particles may act independently
or together in modulating CVD risk. If acting in concert, this might be indicative of shared pathogenic
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mechanisms leading to CVD risk. Thus, in an earlier report from the Prevention of Renal and Vascular
Endstage Disease (PREVEND) study [10], statistical interactions of elevated UAE with multiple
apoB-containing lipoprotein fractions were demonstrated, leading to the conclusion that elevated
UAE and atherogenic apoB lipoproteins characteristic of albuminuric subjects likely do share common
pathogenic mechanisms leading to CVD.
In contrast, for high-density lipoprotein (HDL) in individuals with nephrotic syndrome and
chronic kidney disease (CKD), HDL cholesterol (HDL-C) is within or below normal limits [16].
Additionally, in these individuals, profound changes in the structure and protective features
of HDL particles may occur, including impairments in reverse cholesterol transport, as well as
anti-inflammatory, antioxidant, and antithrombotic functionalities [16]. Accordingly, in the current
study, we hypothesized that various attributes of HDL particles might demonstrate modulation of the
CVD risk associated with elevated UAE, which is potentially indicative of a commonality of pathogenic
pathways. To address this question, we investigated 6,286 participants of the PREVEND study using
nuclear magnetic resonance (NMR) lipoprotein analyses with a particular focus on HDL-associated
parameters along with multivariable Cox proportional hazards risk modeling as a function of UAE
and HDL-associated parameters by NMR to determine risk associations and potential interactions
between UAE and HDL-associated parameters that might underlie CVD risk.
2. Results
2.1. Study Group Characterization
Figure 1 gives an overview of the temporal (baseline screening and second screening)
and parameter analysis scheme for the study. Table 1 gives a summary for subjects at the
baseline evaluation of clinical and laboratory parameters stratified according to UAE as follows:
normoalbuminuria (<30 mg/24 h), microalbuminuria (30 to 300 mg/24 h), and macroalbuminuria
(>300 mg/24 h). Unadjusted ANOVA and chi-square testing results demonstrated significant
differences among the UAE groups for all parameters of Table 1 except for ethanol use. Results
of post-hoc statistical comparisons revealed the following: for the normoalbuminuric versus
microalbuminuric groups, differences in all parameters except for apoA-II; for the normoalbuminuric
versus macroalbuminuric groups, differences in all parameters except for apoA-I and apoA-II/HDL-C;
and for the microalbuminuric versus macroalbuminuric groups, differences in BMI, systolic blood
pressure, creatinine, eGFR, apoA-II, triglycerides, and glucose. With adjustment of ANOVA models for
gender and age and further adjustment for gender, age, apoB, diabetes, past CVD history, and eGFR;
all lipid and lipoprotein markers remained significantly associated with the UAE groups except for
apoA-I, cholesterol, and LDL-C.
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Figure 1. Overview of study design.
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Table 1. Clinical covariates and biomarker levels (mean ± SD or median (interquartile range)) of the study population at the baseline evaluation stratified according to
24 h urinary albumin excretion (UAE) as: normoalbuminuria <30 mg/24 h, microalbuminuria between 30 and 300 mg/24 h, and macroalbuminuria >300 mg/24 h.
Parameter Total Population Normoalbuminuria (86.1% of Subjects) Microalbuminuria Macroalbuminuria p a p b p c
Subjects (%) N = 6286 87.4 11.5 1.1
Age (yrs) 48.7 ± 12.0 47.8 ± 11.8 54.6 ± 11.8 57.3 ± 12.4 <0.001
Females (%) 51.0 53.2 36.8 29.6 <0.001
Cardiac history (%) 3.0 2.1 7.2 10.3 <0.001
Diabetes (%) 2.7 1.7 8.4 18.8 <0.001
Statins (%) 3.7 3.0 7.3 13.2 <0.001
Anti-hypertensives (%) 14.6 12.7 25.6 37.9 <0.001
Current Smoker (%) 31.9 31.6 35.4 18.6 0
Ethanol Use (%) 25.5 25.2 27.4 24.3 0.46
BMI (kg/m2) 26.0 ± 4.1 25.7 ± 3.9 27.7 ± 4.6 29.5 ± 4.5 <0.001 <0.001 <0.001
Systolic BP (mmHg) 128 ± 19 126 ± 18 141 ± 23 151 ± 24 <0.001 <0.001 <0.001
Diastolic BP (mmHg) 74 ± 10 73 ± 9 79 ± 11 82 ± 10 <0.001 <0.001 <0.001
UAE (mg/24 h) 8.93 (6.19–15.61) 8.09 (5.92–11.93) 53.0 (38.0–87.1) 495 (347–1077) <0.001 <0.001 <0.001
Creatinine (µmol/L) 83.4 ± 14.3 82.4 ± 13.3 88.2 ± 18.3 106.9 ± 33.9 <0.001 <0.001 <0.001
eGFR (mL/min/1.7 m2) 84.4 ± 15.0 85.2 ± 14.5 79.7 ± 16.5 67.7 ± 20.2 <0.001 <0.001 <0.001
HDL-C (mmol/L) 1.33 ± 0.40 1.35 ± 0.40 1.21 ± 0.38 1.15 ± 0.31 <0.001 <0.001 <0.001
ApoA-I (µmol/L) 48.0 ± 9.8 48.2 ± 9.8 46.9 ± 9.8 45.8 ± 9.9 <0.001 0.32 0.58
ApoA-II (µmol/L) 19.7 ± 3.7 19.7 ± 3.7 19.4 ± 3.9 18.1 ± 3.6 <0.001 0.013 0.027
ApoA-I/HDL-C (µmol/mmol) 37.6 ± 10.2 37.1 ± 7.9 40.7 ± 9.1 41.7 ± 10.2 <0.001 <0.001 <0.001
ApoA-II/HDL-C (µmol/mmol) 15.8 ± 4.6 15.6 ± 4.5 17.2 ± 5.1 16.7 ± 4.9 <0.001 <0.001 <0.001
Cholesterol (mmol/L) 5.62 ± 1.13 5.58 ± 1.12 5.89 ± 1.13 6.09 ± 1.35 <0.001 0.001 0.24
NonHDL-C (mmol/L) 4.28 ± 1.20 4.22 ± 1.19 4.67 ± 1.21 4.94 ± 1.39 <0.001 <0.001 0.005
LDL-C (mmol/L) 3.66 ± 1.04 3.62 ± 1.03 3.89 ± 1.04 3.98 ± 1.07 <0.001 0.18 0.40
Triglycerides (mmol/L) 1.14 (0.83–1.66) 1.11 (0.81–1.60) 1.43 (1.00–2.20) 1.49 (1.07–2.77) <0.001 <0.001 <0.001
ApoB (g/L) 1.03 ± 0.30 1.01 ± 0.29 1.12 ± 0.32 1.15 ± 0.30 <0.001 <0.001 0.024
Glucose (mmol/L) 4.83 ± 1.08 4.75 ± 0.87 5.37 ± 1.81 5.80 ± 2.70 <0.001 <0.001 <0.001
CRP (mg/L) 1.18 (0.53–2.77) 1.07 (0.49–2.55) 2.08 (0.96–4.32) 2.57 (1.25–6.24) <0.001 <0.001 <0.001
a Significance levels from chi square testing for categorical variables and unadjusted ANOVA for continuous variables. Post-hoc testing revealed significant differences between
normoalbuminuric and microalbuminuric subjects for all parameters except apoA-II; significant differences between normoalbuminuric and macroalbuminuric subjects for all parameters
except apoA-I and apoA-II/HDL-C; and significant differences between microalbuminuric and macroalbuminuric subjects for BMI, systolic blood pressure, creatinine, eGFR, apoA-II,
triglycerides, and glucose. b Significance levels from ANOVA adjusted for gender and age. c Significance levels from ANOVA adjusted for gender, age, apoB, diabetes, past CVD history,
and eGF.
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2.2. CVD Risk Associations at Baseline Screening of UAE and HDL-Associated Parameters
To examine potential associations of UAE and HDL-associated parameters with CVD risk, Cox
multivariable proportional hazards models adjusted for gender and age were formulated with time to
event (from the time of baseline evaluation and extending for median follow-up time of 10.5 years) as a
function of UAE along with separate entry of HDL-C, apoA-I, apoA-II, apoA-I/HDL-C (crude estimate
of apoA-I HDL particle content), and apoA-II/HDL-C (crude estimate of apoA-II HDL particle content).
The results (Table 2) demonstrated in each case significant direct risk association of UAE along with
independent inverse risk associations with HDL-C, apoA-I, and apoA-II; and independent direct risk
associations with apoA-I/HDL-C and apoA-II/HDL-C.
Table 2. Interaction of urinary albumin excretion (UAE) with HDL-related parameters for baseline
evaluation data as assessed by Cox proportional hazards models of cardiovascular event occurrence
adjusted for gender and age. Hazard ratios are per SD unit for all variables.
Models Model without Interaction Model with Interaction
Parameters HR 95% CI p HR 95% CI p
UAE 1.11 1.00–1.23 0.036 1.16 1.02–1.31 0.023
HDL-C 0.62 0.53–0.74 <10−6 0.61 0.51–0.73 <10−6
interaction 1.07 0.94–1.22 0.34
UAE 1.15 1.04–1.27 0.005 1.16 1.04–1.29 0.006
ApoA-I 0.77 0.67–0.88 <10−3 0.76 0.66–0.88 <10−3
interaction 1.02 0.93–1.11 0.72
UAE 1.16 1.05–1.28 0.003 1.16 1.05–1.29 0.004
ApoA-II 0.89 0.78–1.01 0.067 0.88 0.77–1.01 0.068
interaction 1.01 0.93–1.11 0.76
UAE 1.11 1.01–1.23 0.036 1.17 1.05–1.30 0.003
ApoA-I/HDL-C 1.26 1.14–1.39 <10−5 1.32 1.19–1.47 <10−6
interaction 0.91 0.84–0.99 0.019
UAE 1.11 1.01–1.23 0.035 1.15 1.04–1.28 0.009
ApoA-II/HDL-C 1.34 1.20–1.51 <10−6 1.40 1.24–1.58 <10−6
interaction 0.93 0.85–1.01 0.10
Interactions between UAE and the HDL-associated parameters were also examined by inclusion
of corresponding interactions terms into the gender- and age-adjusted models. Results (Table 2)
demonstrated significant interaction with UAE only for apoA-I/HDL-C. Moreover, when models
were concurrently adjusted for gender, age, apoB concentration, diabetes, past CVD history, CRP
concentration, and eGFR; again significant interaction with UAE was demonstrated only for
apoA-I/HDL-C (Table 3).
Table 3. Interaction of UAE with HDL-related parameters for baseline evaluation data as assessed by
Cox proportional hazards models of cardiovascular event occurrence concurrently adjusted for gender,
age, apoB concentration, diabetes, past CVD history, C-reactive protein (CRP) concentration, and eGFR.
Models Model without Interaction Model with Interaction
Parameters HR 95% CI p HR 95% CI p
UAE 1.04 0.94–1.16 0.46 1.10 0.97–1.26 0.14
HDL-C 0.74 0.61–0.88 <10−3 0.72 0.59–0.86 <10−3
interaction 1.10 0.96–1.26 0.16
UAE 1.07 0.96–1.19 0.21 1.07 0.95–1.19 0.26
ApoA-I 0.73 0.62–0.85 <10−4 0.73 0.662–0.86 <10−3
interaction 1.00 0.89–1.12 0.96
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Table 3. Cont.
Models Model without Interaction Model with Interaction
Parameters HR 95% CI p HR 95% CI p
UAE 1.06 0.96–1.18 0.26 1.07 0.96–1.19 0.22
ApoA-II 0.76 0.65–0.89 <10−3 0.75 0.64–0.89 <10−3
interaction 1.03 0.92–1.14 0.63
UAE 1.04 0.94–1.16 0.44 1.11 0.99–1.25 0.078
ApoA-I/HDL-C 1.10 0.96–1.26 0.16 1.16 1.01–1.34 0.036
interaction 0.90 0.81–0.99 0.025
UAE 1.05 0.94–1.16 0.41 1.07 0.96–1.20 0.23
ApoA-II/HDL-C 1.16 1.00–1.34 0.52 1.19 1.02–1.39 0.029
interaction 0.95 0.86–1.05 0.29
2.3. Lipoprotein NMR Analyses
Approximately three to four years after study initiation, blood and urine were again collected on
a new screening round in which UAE determinations and NMR lipid and lipoprotein analyses were
performed on the subjects of Table 1. The results from the NMR analyses, according to albuminuria
status, are given in Table 4 for concentrations of total HDL particles (HDL-P), large HDL particle (large
HDL-P), medium HDL particles (medium HDL-P), small HDL particles (small HDL-P), mean HDL
size, and concentrations of HDL-C and apoA-I, as well as calculated values of apoA-I/HDL-C and
apoA-I/HDL-P. From Table 4, trends in parameters with increasing UAE status are demonstrated.
Unadjusted ANOVA results demonstrated significant differences among the UAE groups for all
parameters of Table 4. Table 4 also presents results of post-hoc statistical comparisons between
albuminuria groups. With adjustment of ANOVA models for gender and age and further adjustment
for gender, age, apoB, diabetes, past CVD history, and eGFR, all NMR lipoprotein markers remained
significantly associated with the UAE groups except for medium and small HDL-P and the ratio of
apoA-I/HDL-P.
Lastly, multiple regression analysis with total apoA-I concentration as a function of large, medium,
and small particles was used to estimate the mean number of apoA-I molecules/particle for the three
subfractions (Appendix A). Results were as follows: large HDL: 4.49 ± 0.014, p < 10−6; medium HDL:
2.55 ± 0.007, p < 10−6; and small HDL: 1.68 ± 0.003, p < 10−6).
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Table 4. NMR-derived biomarker levels (mean ± SD) in the study population at second screening round stratified according to 24 h urinary albumin excretion (UAE)
as: normoalbuminuria <30 mg/24 h, microalbuminuria between 30 and 300 mg/24 h, and macroalbuminuria >300 mg/24 h. Ranges of HDL particle diameters were:
large HDL (9.6–13 nm), medium HDL (8.1–9.5 nm), and small HDL (7.4–8.0 nm).
Parameter Total Population Normoalbuminuria(86.1% of subjects) Microalbuminuria Macroalbuminuria p
a p b p c
HDL-P (µmol/L) 21.14 ± 2.74 21.23 ± 2.71 20.57 ± 2.83 20.40 ± 3.23 <0.001 <0.001 0.003
Large HDL-P (µmol/L) 1.81 ± 1.29 1.86 ± 1.30 1.50 ± 1.21 1.49 ± 1.16 <0.001 0.001 0.009
Medium HDL-P (µmol/L) 5.15 ± 2.19 5.25 ± 2.19 4.59 ± 2.11 4.06 ± 2.09 <0.001 <0.001 0.18
Small HDL-P (µmol/L) 14.18 ± 2.87 14.13 ± 2.88 14.48 ± 2.75 14.85 ± 3.06 <0.001 0.65 0.53
HDL Size (nm) 8.97 ± 0.45 8.99 ± 0.45 8.84 ± 0.45 8.82 ± 0.45 <0.001 <0.001 0.005
HDL-C (mmol/L) 1.33 ± 0.32 1.34 ± 0.31 1.23 ± 0.32 1.21 ± 0.34 <0.001 <0.001 0.009
ApoA-I (µmol/L) 45.1 ± 7.8 45.4 ± 7.7 43.0 ± 7.9 42.5 ± 8.6 <0.001 <0.001 0.023
ApoA-I/HDL-C (µmol/mmol) 34.5 ± 2.9 34.4 ± 2.9 35.5 ± 3.0 35.9 ± 3.1 <0.001 <0.001 <0.001
ApoA-I/HDL-P (molecules/particle) 2.13 ± 0.21 2.14 ± 0.21 2.09 ± 0.20 2.08 ± 0.21 <0.001 0.25 0.38
a Significance levels from unadjusted ANOVA. Post-hoc testing revealed significant differences between normoalbuminuric and microalbuminuric subjects for all parameters; significant
differences between normoalbuminuric and macroalbuminuric subjects for all parameters except small HDL-P and ApoA-I/HDL-P; and no significant differences between microalbuminuric
and macroalbuminuric subjects for any of the parameters. b Significance levels from ANOVA adjusted for gender and age. c Significance levels from ANOVA adjusted for gender, age,
apoB, diabetes, past CVD history, and eGFR. Abbreviations: HDL-P, total HDL particle concentration; Large HDL-P, large HDL particle concentration; Medium HDL-P, medium HDL
particle concentration; and Small HDL-P, small HDL particle concentration.
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2.4. CVD Risk Associations at Second Screening of UAE and HDL-associated Parameters
Results from Table 2 revealed significant interaction for UAE with the apoA-I/HDL-C ratio,
a crude measure of the apoA-I content of HDL particles. However, since NMR lipoprotein analysis
provides total HDL particle concentrations and apoA-I concentrations, it thus makes it possible to
calculate the mean number of apoA-I molecules per HDL particle. To examine potential associations
of UAE and HDL-associated NMR parameters with CVD risk, especially as related to the apoA-I
content of HDL particles, Cox multivariable proportional hazards models (from the time of the second
screening round and extending for median follow-up time of 8.3 years) adjusted for gender and age
were formulated with time to event as a function of UAE along with a separate entry of each of
the nine parameters of Table 4. The results (Table 5) demonstrated, in each case, significant direct
risk association of UAE along with independent inverse risk associations with HDL-P, large HDL-P,
medium HDL-P, HDL size, HDL-C, apoA-I, and the apoA-I/HDL-P; and independent direct risk
association for the apoA-I/HDL-C ratio.
Table 5. Interaction of UAE with HDL-related parameters for second screening round as assessed by
Cox proportional hazards models of cardiovascular event occurrence adjusted for gender and age.
Hazard ratios are per SD unit for all variables.
Models Model without Interaction Model with Interaction
Parameters HR 95% CI p HR 95% CI p
UAE 1.21 1.12–1.32 <10−5 1.23 1.12–1.34 <10−5
HDL-P 0.83 0.75–0.93 0.001 0.82 0.73–0.93 0.004
interaction 1.02 0.95–1.10 0.56
UAE 1.21 1.11–1.31 <10−5 1.23 1.13–1.34 <10−5
Large HDL-P 0.74 0.64–0.85 <10−4 0.72 0.62–0.84 <10−4
interaction 1.05 0.96–1.16 0.30
UAE 1.20 1.10–1.30 <10−4 1.28 1.16–1.40 <10−5
Medium HDL-P 0.74 0.65–0.84 <10−5 0.70 0.61–0.81 <10−5
interaction 1.11 1.01–1.22 0.029
UAE 1.22 1.13–1.33 <10−5 1.24 1.14–1.35 <10−6
Small HDL-P 1.11 0.99–1.24 0.07 1.15 1.02–1.30 0.024
interaction 0.93 0.86–1.01 0.10
UAE 1.20 1.10–1.30 <10−4 1.24 1.13–1.36 <10−5
HDL Size 0.70 0.61–0.80 <10−6 0.67 0.58–0.77 <10−6
interaction 1.08 0.99–1.18 0.10
UAE 1.19 1.10–1.29 <10−4 1.29 1.14–1.37 <10−5
HDL-C 0.69 0.60–0.79 <10−6 0.66 0.57–0.76 0.004
interaction 1.08 1.00–1.18 0.06
UAE 1.20 1.11–1.30 <10−4 1.24 1.14–1.37 <10−5
ApoA-I 0.74 0.65–0.84 <10−5 0.71 0.62–0.81 <10−5
interaction 1.07 0.99–1.16 0.11
UAE 1.19 1.09–1.29 <10−4 1.23 1.12–1.35 <10−5
ApoA-I/HDL-C 1.37 1.22–1.55 <10−6 1.43 1.25–1.62 <10−6
interaction 0.94 0.86–1.02 0.11
UAE 1.21 1.11–1.31 <10−5 1.26 1.15–1.37 <10−6
ApoA-I/HDL-P 0.74 0.65–0.85 <10−4 0.71 0.61–0.82 <10−5
interaction 1.10 1.00–1.20 0.039
HDL-P, total HDL particle concentration; Large HDL-P, large HDL particle concentration; Medium HDL-P, medium
HDL particle concentration; and Small HDL-P, small HDL particle concentration.
Interactions between UAE and the HDL-associated NMR parameters were also examined by
including corresponding interaction terms into the gender and age adjusted models. The results
(Table 5) demonstrated significant interaction for UAE with medium HDL-P (p = 0.029) and with the
apoA-I/HDL-P ratio (p = 0.039) and close approach to significance for HDL-C (p = 0.060). Results were
essentially the same when models were concurrently adjusted for gender, age, apoB concentration,
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diabetes, past CVD history, CRP, and eGFR (Table 6). The results suggest a role for the apoA-I content
of HDL particles and medium HDL-P and potentially for HDL-C in the association of UAE with
CVD risk.
Table 6. Interaction of UAE with HDL-related parameters for second screening round as assessed by
Cox proportional hazards models of cardiovascular event occurrence adjusted for gender, age, apoB,
diabetes, past CVD history, CRP, and eGFR. Hazard ratios are per SD unit for all variables.
Models Model without Interaction Model with Interaction
Parameters HR 95% CI p HR 95% CI p
UAE 1.13 1.05–1.24 0.003 1.16 1.076–1.27 0.002
HDL-P 0.88 0.79–0.99 0.030 0.86 0.77–0.968 0.018
interaction 1.04 0.96–1.12 0.36
UAE 1.14 1.05–1.24 0.003 1.16 1.06–1.27 0.001
Large HDL-P 0.86 0.74–1.01 0.060 0.84 0.72–0.99 0.037
interaction 1.05 0.96–1.16 0.28
UAE 1.13 1.04–1.243 0.006 1.21 1.09–1.33 <10−3
Medium HDL-P 0.801 0.71–0.92 0.002 0.76 0.66–0.88 <10−3
interaction 1.12 1.02–1.23 0.018
UAE 1.14 1.05–1.24 0.003 1.15 1.06–1.26 0.001
Small HDL-P 1.05 0.93–1.18 0.44 1.08 0.95–1.23 0.24
interaction 0.94 0.87–1.03 0.19
UAE 1.13 1.04–1.24 0.004 1.17 1.07–1.29 <10−3
HDL Size 0.80 0.69–0.92 0.002 0.77 0.66–0.90 <10−3
interaction 1.07 0.98–1.17 0.14
UAE 1.13 1.04–1.24 0.004 1.18 1.08–1.31 <10−3
HDL-C 0.79 0.68–0.91 0.002 0.76 0.65–0.88 <10−3
interaction 1.08 1.00–1.187 0.049
UAE 1.14 1.04–1.24 0.003 1.18 1.08–1.30 <10−3
ApoA-I 0.83 0.73–0.95 0.006 0.80 0.70–0.92 0.002
interaction 1.08 0.99–1.17 0.08
UAE 1.13 1.04–1.23 0.006 1.17 1.06–1.29 0.002
ApoA-I/HDL-C 1.23 1.08–1.40 0.002 1.27 1.10–1.45 <10−3
interaction 0.94 0.87–1.03 0.18
UAE 1.14 1.05–1.24 0.003 1.18 1.08–1.30 <10−3
ApoA-I/HDL-P 0.86 0.74–1.00 0.044 0.81 0.69–0.95 0.011
interaction 1.09 1.00–1.20 0.048
HDL-P, total HDL particle concentration; Large HDL-P, large HDL particle concentration; Medium HDL-P, medium
HDL particle concentration; and Small HDL-P, small HDL particle concentration.
The effects of the addition of significant interaction terms are illustrated (see Appendix B for
our approach to graphical modeling) for the ratio of apoA-I/HDL-P (Figure 2), and medium HDL-P
(Figure 3), and for the nearly significant HDL-C interaction (Figure S1), and for the marginally
significant HDL particle size interaction (Figure S2). In each case, the top panels show hazard ratio
contours over relevant domains of UAE and HDL-associated parameters. In each case, increasing UAE
shows increased risk, whereas increasing values of HDL-associated parameters are protective except
for apoA-I/HDL-C. However, as illustrated in the bottom panels, when respective interaction terms
in each of the cases are added to models, increasing UAE interacts with increasing HDL parameter
values to intensify risk except for apoA-I/HDL-C where, instead, decreasing apoA-I/HDL-C interacts
with increasing UAE to intensify risk.
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2.5. Effects of Gender, Age, and Co-Morbidities on Outcomes and Interaction of UAE with ApoA-I/IHDL-P
Effects on outcome of the parameters included in the fully-adjusted model are given in Table 7.
Hazard ratios reveal risk with increasing age, gender (males > females), apoB concentration, diabetes,
past history of CVD, CRP concentration, and decreasing eGFR.
Table 7. Risk model results of second screening round examining interaction of UAE with
apoA-I/HDL-C with adjustments for gender, age, apoB, diabetes, past CVD history, CRP, and eGFR.
Hazard ratios are per SD unit for continuous variables.
Parameters HR 95% CI p
Gender 2.16 1.65–2.83 <10−6
Age 1.85 1.59–2.14 <10−6
ApoB Concentration 1.22 1.08–1.37 <10−3
Diabetes 1.61 1.08–2.40 0.020
Past CVD History 2.27 1.64–3.15 <10−5
CRP Concentration 1.18 1.03–1.34 0.013
eGFR 0.88 0.78–1.00 0.053
UAE 1.18 1.08–1.30 <10−3
ApoA-I/HDL-C 0.81 0.69–0.95 0.011
UAE x ApoA-I/HDL-P 1.09 1.00–1.20 0.048
ApoB, apolipoprotein B; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; UAE, urinary albumin
excretion; and apoA-I, apolipoprotein A-I.
The effects of gender and age on the interaction of UAE with apoA-I/HDL-P were also examined.
The results (HR, 95% CI, p-value) of analyses stratified by gender for the interaction term were
significant for males (1.13, 1.02–1.26, p = 0.023) but non-significant for females. The results of analyses
stratified by age (quartiles) for the interaction term were significant for quartile 4 (1.15, 1.00–1.32,
p = 0.044) but non-significant for the three younger age quartiles. Thus, interaction of UAE with
apoA-I/HDL-P was accentuated in males and in older individuals.
2.6. CVD Risk Relationships of ApoA-I/HDL-C and ApoA-I/IHDL-P
The apoA-I/HDL-C ratio was formulated as a crude estimate of HDL particle apoA-I content.
The ratio was directly associated with CVD risk from results of both baseline (Table 2) and second
screening (Table 5). Yet apoA-I/HDL-P, presumably also an estimator of HDL particle apoA-I content,
instead revealed inverse correlation with risk. Appendix C, and Figures S3 and S4 present the rationale
underlying this inverse relationship.
3. Discussion
The current work set-up as a dual-phase study utilizing multivariable risk modeling investigated
incident CVD in a cohort of individuals of the PREVEND study as a function of UAE and measures of
apoA-I content of HDL particles and concentrations of size-based HDL subfractions. In addition
to confirming previous findings of risk associated with elevated UAE [1–8], baseline screening
results using standard lipid and lipoprotein analyses revealed significant risk associations for HDL-C,
apoA-I, and apoA-I/HDL-C. These findings were subsequently confirmed and extended using NMR
lipoprotein analyses on samples collected four years later in risk models adjusted for gender, age, apoB,
diabetes, past CVD history, CRP and eGFR. The results revealed an inverse association with risk for
HDL-C, apoA-I, HDL-P, apoA-I/HDL-P, large HDL-P, and medium HDL-P, and a direct association for
apoA-I/HDL-C. Moreover, in terms of interactions, further modeling revealed significant interactions
between UAE and apoA-I/HDL-P and between UAE and medium HDL-P. In both cases, inclusion
of interaction terms in risk models resulted in amplified risk at concurrently high levels of UAE
and apoA-I/HDL-P and at concurrently high levels of UAE and concentration of medium-size HDL
particles. We interpret these results to be consistent with our hypothesis that compositional features
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of HDL particles modulate the CVD risk associated with elevated UAE; furthermore, such findings
may be indicative of pathogenic mechanisms shared by high UAE and compositional features of HDL
particles in the development of CVD risk.
The results of our study demonstrated an independent protective effects against CVD risk for
apoA-I/HDL-P. However, upon interaction with elevated UAE, the risk increased. This reversal is
likely related to alterations in HDL structure and function in the setting of proteinuria resulting in
pro-atherogenic transformation of HDL, especially as related to reverse cholesterol transport (RCT) [16].
Multiple factors associated with proteinuria have been shown to contribute to pro-atherogenic
alterations in HDL that affect RCT by impairing maturation of HDL particles, particularly as related
to cholesteryl ester enrichment. These include: 1. deficiency of lecithin-cholesteryl acyltransferase
(LCAT) [17] as LCAT together with apoA-I mediates esterification of free cholesterol, although elevated
LCAT activity has also been reported in proteinuria [18]; 2. hypoalbuminemia as albumin delivers
significant amounts of free cholesterol from peripheral tissues to HDL particles, as it is a sign of
inflammation [19]; 3. increased levels of cholesterol ester transfer protein (CETP) resulting in depletion
of HDL particle cholesterol esters [20]; 4. decreased levels of the SRB1 hepatic HDL receptor resulting in
decreased hepatic uptake of cholesteryl ester [21]; and 5. increased levels of the hepatic HDL endocytic
receptor resulting in decreased apoA-I and HDL levels via increase in apoA-I mediated uptake of
lipid-poor HDL [22]. In addition to proteinuria-associated RCT impairment, other atheroprotective
HDL functions including anti-oxidant, anti-inflammatory, and anti-thrombotic activities would
also likely be compromised with elevated UAE as in chronic renal disease [23–25]. Generation of
dysfunctional HDL ensuing from these processes especially as affecting apoA-I would likely underlie
the observed reversal of CVD risk association by apoA-I content of HDL from atheroprotective to
atherogenic upon interaction with elevated UAE.
The results of our study also demonstrated independent protective effects against CVD risk
by medium-size HDL particle concentration. However, again upon interaction with elevated UAE,
the risk increased. Similar to apoA-I/HDL-P, medium HDL in the setting of elevated UAE could
also develop into a source of pro-atherogenic HDL. Why this was not the case for concentrations of
large and small HDL is not clear. Regarding large HDL, proportional hazards regression results with
and without interaction were similar to those of medium HDL, except that the interaction term did
not achieve statistical significance (p = 0.65) for large HDL. We speculate that this may relate to the
generally greater estimated load of apoA-I carried by medium HDL particles (13.14 µM) in comparison
to large HDL particles (8.12 µM) giving rise to a larger total pro-atherogenic load from medium HDL
particles. The case for small-HDL particle concentration in UAE-associated risk was different in that
interaction with elevated UAE did not achieve statistical significance.
In general consideration of HDL particle concentrations, the results of our study demonstrated
that with increasing albuminuria, there were decreased concentrations of total, large, and medium
size HDL particles, smaller HDL mean particle size, and increased concentration of small size HDL
particles. These findings were generally consistent with the known lower levels of HDL2 and higher
levels of HDL3 particles in nephrotic syndrome patients resulting from dysfunctional alterations
of HDL secondary to impaired HDL particle maturation [16,26] and the lower total HDL particle
concentration and lower mean HDL particle size in women with mild elevations in UAE [9].
Limitations in our study should be acknowledged. Although analysis results in the baseline
screening round indicated potential for the apoA-II content of HDL to play a role in UAE-associated
CVD risk, apoA-II levels in the second screening round were not available for confirmation.
Additionally, data relating to other HDL constituents that likely play major roles in HDL metabolic,
anti-inflammatory, and anti-thrombotic functionality were not available for assessment of interaction
with UAE in CVD risk. In addition, the nature of the study did not allow us to delineate causal
relationships in the complicated interplay between elevated UAE and aspects of HDL functionality that
contribute to the process of atherogenesis leading to CVD. Moreover, actual experimental data relating
directly to changes in HDL particle structure, and especially function, were not available. However,
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our approach of suing statistical interactions to reveal effects of HDL compositional characteristics
in the context of increasing UAE on risk can be anticipated to be helpful in select subpopulations of
subjects, in which documentation of HDL functionality and metabolomics studies may be particularly
insightful. The strengths of our study included a design in which preliminary findings determined
at study initiation from a large prospective population-based study (N = 6,286) could be extended
from results of a second round of data collection on the same subjects approximately four years
after study initiation. Furthermore, the second round of data collection afforded NMR-based lipid
and lipoprotein analyses, including determinations of mean HDL particle size and concentrations
of HDL-C, apoA-I, and HDL particle subfractions (large, medium, and small), with the use of a
state-of-the-art deconvolution algorithm for the NMR data.
To summarize, the current study was undertaken to determine whether HDL particles share
common pathogenic pathways with elevated UAE in development of CVD risk. The study
involved proportional hazards multivariable modeling on subjects of PREVEND, a large prospective
population-based study, assessing risk as a function UAE and of HDL-associated parameters that were
determined by NMR lipid and lipoprotein analyses. The results demonstrated not only significant
risk associations for elevated UAE and for multiple HDL-associated parameters, but moreover, and
importantly, significant interactions of elevated UAE with apoA-I/HDL-P, a measure of HDL apoA-I
content, and with concentration of medium size HDL particles. We believe that our study findings are
consistent with HDL particles sharing pathogenic pathways with elevated UAE in CVD risk. Future
studies should be oriented toward pathway characterizations.
4. Materials and Methods
4.1. Study Population
The study population was derived from PREVEND, a large general population-based, prospective
cohort study begun in 1997 aiming to explore the role of albuminuria with CVD and renal disease [27].
Briefly, a questionnaire to all inhabitants of the city of Groningen, the Netherlands, aged 28–75 years
(N = 85,421) was sent requesting an early morning urine specimen. The response rate was 48%
(N = 40,856), of which 9,966 had urine albumin levels ≥10 mg/L, while 30,890 had urine albumin
<10 mg/L. Pregnancy, type-1 type-2 diabetic individuals using insulin were exclusions. All subjects
with urine albumin ≥10 mg/L (N = 7768) were combined with a random group of individuals with
urine albumin <10 mg/L (N = 3395). Of this group, 8,592 individuals completed an additional
screening program to comprise the PREVEND study cohort. Further exclusion of subjects without
NMR lipoprotein analyses constituted the current study population (N = 6286). The PREVEND study
was approved by the Medical Ethics Committee of the University of Groningen, the Netherlands,
(Approval code 96/01/022, Approval date 23 February 1996). Informed written consent was obtained
from all participants. The study adhered to the ethical principles set by the Declaration of Helsinki.
4.2. Clinical Parameters and Biomarkers
Cardiac history (hospitalization for myocardial infarction, revascularization procedures,
or obstructive coronary artery disease) was acquired from questionnaires. Characterization of diabetes
was either as fasting plasma glucose ≥7.0 mmol/L, self-report of physician diagnosis, or use of
anti-diabetic medications. Medication use was retrieved via Groningen pharmacy dispensing data [28].
Smoking status was as either current smoker or not; ethanol use was either as one or less drinks
per day or more than one drink per day. Body mass index (BMI) was calculated as weight divided
by height squared (kg/m2). Blood pressure was measured in the supine position for 10 minutes
at 1-minute intervals using automatic instrumentation (Dinamap XL Model 9300; Johnson-Johnson
Medical, Tampa, FL, USA); reported values were means of the last two recordings [29].
UAE at study entry and second examination were determined as the mean of two 24-h collections
over two consecutive days. Nephelometry (BNII, Dade Behring, Marburg, Germany) was used to
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measure urinary albumin concentration. Analyses of blood biomarker levels at study initiation were
performed on overnight-fasted plasma and sera. Levels of creatinine, HDL-C, apoA-I, apoA-II, total
cholesterol, triglycerides, apoB, glucose, and CRP were determined by standard techniques [30,31].
Estimated glomerular filtration rate (eGFR) was determined using the serum creatinine-based Chronic
Kidney Disease Epidemiology Collaboration (CDK-EPI) equation [32]. NonHDL-C was calculated
as the difference between total cholesterol and HDL-C. LDL-C levels were estimated using the
Friedewald equation.
Concentrations of HDL-C, apoA-I, HDL-P, large HDL-P, medium HDL-P, and small HDL-P and
HDL size were determined using nuclear magnetic resonance (NMR) spectroscopy on plasma samples
collected at second screening. NMR MetaboProfile Analysis was used with the LP-4 deconvolution
algorithm (LabCorp, Morrisville, NC, USA) for determination of analyte concentrations from NMR
spectra collected on a Vantera Clinical Analyzer, as previously described [33,34]. Diameter range
estimates for the NMR-derived HDL particle subfractions were as follows: large HDL (9.6–13 nm),
medium HDL (8.1–9.5 nm), and small HDL (7.4–8.0 nm).
4.3. Outcome
Incident outcome events followed over time included CVD-related mortality and hospitalizations
including acute MI, acute and subacute ischaemic heart disease, coronary artery bypass grafting, and
percutaneous transluminal coronary angioplasty. Survival time was taken as date of initial urine
collection (1997–1998) to date of first CV event or to 31 December 2008. For anyone lost to follow-up
(396 of the overall cohort of 8592 participants), censoring date was date of removal from the municipal
registry. Mortality data and causes of death were acquired by record linkage with the Dutch Central
Bureau of Statistics. CVD morbidity data were obtained from PRISMANT, the Dutch national registry
of hospital discharge diagnoses.
4.4. Data Analysis
Statistical and graphical analyses were performed using Statistica 10.0 (StatSoft, Inc., Tulsa,
OK, USA). Results are reported as means ± SD for normally distributed variables and as medians
(interquartile range) for non-normal variables. Differences among groups were assessed by chi-square
testing for categorical variables and by ANOVA for continuous variables using Bonferroni correction
for multiple comparisons. Non-normal variables were log-transformed for analyses. Multivariable
Cox proportional hazards modeling was used to follow cardiovascular outcomes over time with
continuous independent variables standardized by transformation to distributions with means of zero
and standard deviations of one. Hazard ratios (HR) are per SD unit. Interactions between risk variables
were assessed by the inclusion of multiplicative interaction terms into the base models. Two-sided
p-values < 0.05 were considered statistically significant. The proportional hazards assumption was
verified by correlation analysis of survival time with scaled Schoenfeld residuals.
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Appendix A. Estimates of Mean Number of apoA-I Molecules per Particle and Mean apoA-I
Concentrations of Large, Medium, and Small HDL Subfractions
Lastly, multiple regression analysis with total apoA-I concentration as a function of large, medium,
and small particles was used to estimate the mean number of apoA-I molecules/particle for the
three subfractions. From these values and the total particle concentrations of the subfractions, the
concentrations of apoA-I in each of the three subfractions were estimated. Parameters are defined
as follows:ApoA1 = total apoA-I concentration (µM), L = large HDL particle concentration (µM),
M = medium HDL particle concentration (µM), S = small HDL particle concentration (µM), NL = mean
number of apoA-I molecules per large HDL particle, NM = mean number of apoA-I molecules per
medium HDL particle, and NS = mean number of apoA-I molecules per small HDL particle.
The mass balance equation for total apoA-I concentration is as follows:
ApoA1 = NL × L + NM × M + NS × S
ApoA1, L, M, and S were measured for each patient in the study. Thus, multiple regression
analysis can be performed with apoA1 as a function of L, M, and S. The resulting regression coefficients
will represent estimates of NL, NM, and NS which can then be multiplied by L, M, and S, respectively
to generate the apoA-I concentrations of each of the subfractions.
Results for number of apoA-I molecules per particle were as follow: large HDL: 4.49 ± 0.014,
p < 10−6; medium: 2.55 ± 0.007, p < 10−6; and small HDL: 1.68 ± 0.003, p < 10−6). Results for apoA-I
concentration were: large HDL: 8.12 ± 0.073 µM, medium HDL: 13.14 ± 0.070 µM, and small HDL:
23.83 ± 0.061 µM.
Appendix B. Approach to Graphical Modeling of CVD Risk Contours without and
with Interactions
Illustrations of interactions of UAE with HDL-associated continuous variables were performed
analytically from Cox regression models to give contour plots of HR as a function of UAE and
HDL-associated parameters. Using apoA-I as an example, this would involve evaluation of the
expression for HR as:
exp(βUAE × UAE + βapoA-I × apoA-I + βinteract × UAE × apoA-I)
Results are presented as 3-dimensional plots showing HR as a surface extending over clinically
relevant domains of UAE and HDL-associated parameters.
Appendix C. Rationale for inverse correlation of apoA-I/HDL-P with apoA-I/HDL-C
To investigate the inverse correlation, a scatter plot of apoA-I/HDL-P versus apoA-I/HDL-C was
generated (Figure S3). The plot revealed an inverse relationship between the two (r = −0.78, p < 0.0001)
consistent with the CVD risk association results.
To explore effects of interaction of apoA-I/HDL-C with UAE, plots of risk as a function of UAE
and apoA-I/HDL-C without and with interaction between the two were generated (Figure S4) noting
that the interaction term between UAE and apoA-I/HDL-C demonstrated only a marginal approach
to significance (Table 4; HR = 0.94, p = 0.11). The risk plot without interaction demonstrated additive
effects on risk for increasing UAE and increasing apoA-I/HDL-C. The risk plot with interaction
demonstrated mainly attenuation of the direct association of apoA-I/HDL-C with risk.
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Regarding the basis for the inverse correlation, our underlying assumption borne out by
correlation analysis regarding apoA-I concentration is that there is a direct linear relationship of
apoA-I concentration with HDL-P (r = 0.83, p < 10−6) and that there is a direct linear relationship of
apoA-I with HDL-C (r = 0.95, p < 10-6). Thus,
ApoA-I = k1 × HDL-P and ApoA-I = k2 × HDL-C
Rearranging the equations gives,
ApoA-I/HDL-P = k1 and ApoA-I/HDL-C = k2
Adding together the two previous equations gives,
ApoA-I/HDL-P + ApoA-I/HDL-C = k1 + k2
Solving the previous equation for ApoA-I/HDL-P gives,
ApoA-I/HDL-P = (k1 + k2) − ApoA-I/HDL-C
We conclude that ApoA-I/HDL-P and ApoA-I/HDL-C have an inverse relationship.
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